Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, has unveiled new clinical evidence in support of Extracorporeal Blood Purification at the 6th Asia Pacific Acute Kidney Injury and Continuous Renal Replacement Therapy (APAC AKI CRRT) Conference 2025 held in Bangkok, Thailand from Oct 2-4, 2025.
Vantive showcased the company’s innovation in CRRT and multi-organ support and reaffirmed its commitment to lifesaving critical care innovation as a sponsor for a consensus paper for Extracorporeal Blood Purification as well as a separate study of patients in the intensive care setting.
Developed by a group of Asia-Pacific experts, the two papers provided a perspective of sepsis and hyperinflammatory conditions, challenges faced by Malaysian ICUs equip clinicians and the capabilities needed to act decisively in critical care settings.
Professor Nattachai Srisawat, MD, PhD from Thailand, lead author of the consensus, said: “Our work to develop the consensus and promote its recommendations among clinicians across Asia Pacific at the AKI CRRT conference is a testament to the power of collaboration.
“By partnering with Vantive, we are able to take the latest research in acute kidney injury and translate it into practical, life-saving therapies that directly benefit patients in Thailand, Malaysia, and beyond. This is about building a regional network of expertise to combat organ failure more effectively.”
Professor Pham Thi Ngoc Thao of Cho Ray Hospital, Vietnam, who was involved in the consensus commented: “In critical care, every minute counts. Vantive’s commitment to advancing multi-organ support gives clinicians a new level of confidence in the most challenging situations.
“This collaboration is crucial for institutions like Cho Ray Hospital, as it empowers us to adopt cutting-edge technologies and share our experiences to improve outcomes for our most critically ill patients in Vietnam, Malaysia and more.”
Vantive is on a mission to extend lives and expand possibilities. The company highlighted the research alongside its innovation to extend the impact in CRRT and multi-organ support at the AKI CRRT conference.
The company’s participation in the conference reinforces its commitment to advancing critical care knowledge in collaboration with hospitals, ongoing research and investment in education, where acute kidney injury (AKI) in Malaysia continues to be a key challenge in intensive care units and contributes to longer hospital stays and higher treatment costs.
Dr Kuljinder Singh, APAC medical director at Vantive said: “As a leader in vital organ therapies, we are proud to work with the clinical community to advance lifesaving critical care therapies with systems capable of delivering continuous renal replacement therapy as well as multi-organ support.
“We continue to pursue novel diagnostic and therapeutic options including a new approach to sepsis management.”
